Cartesian Therapeutics In...

NASDAQ: RNAC · Real-Time Price · USD
11.58
0.25 (2.21%)
At close: Aug 18, 2025, 10:55 AM

Cartesian Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.03M 34.17M 38.91M 47.94M 54.1M 25.91M 26M 34.53M 48.69M 82.72M 110.78M 123.92M 127.64M 108.03M 85.08M 67.09M 47.31M 27.65M
Cost of Revenue
n/a 196K 379K 651K 840K 1.27M 1.7M 2.04M 2.39M 2.26M 2.29M 1.68M 1.14M 644K n/a n/a n/a n/a
Gross Profit
728K 33.98M 38.53M 47.29M 53.26M 24.64M 24.3M 32.49M 46.3M 80.46M 108.49M 122.24M 126.49M 107.38M 85.08M 67.09M 47.31M 27.65M
Operating Income
-88.01M -52.44M -43.9M -53.5M -48.99M -81.38M -86.42M -58.58M -47.11M -14.62M 14.54M 27.11M 26.74M 13.33M -4.6M -16.57M -28.34M -45.16M
Interest Income
9.13M 7.39M 7.39M n/a n/a n/a n/a 1.14M 1.85M 2.06M 2.07M 941K 242K 47K 44K 35K 24K 12K
Pretax Income
-35.97M -38.02M -77.14M -263.83M -248.65M -273.87M -238.71M -36.45M -35.66M -15.67M 34.77M 41.54M 47.69M 43.65M -9.72M -37.54M -45.21M -73.85M
Net Income
-36.26M -38.31M -77.42M -244.83M -229.65M -254.87M -219.71M -36.16M -35.05M -15.06M 35.38M 41.73M 31.72M 27.69M -25.69M -53.37M -45.21M -73.85M
Selling & General & Admin
29.2M 28.99M 30.13M 45.21M 45.26M 44.34M 40.58M 24.13M 22.75M 22.38M 21.57M 21.07M 20.67M 19.1M 18.93M 18.47M 18.07M 19.54M
Research & Development
52.25M 50.04M 45.1M 56.23M 57.83M 62.95M 71.84M 68.38M 71.91M 73.31M 72.38M 73.73M 78.14M 73.42M 68.74M 63.51M 56.52M 52.78M
Other Expenses
7.58M 7.58M 7.58M -62K -62K 183K 438K 500K 500K 255K n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
89.03M 86.61M 82.81M 101.44M 103.09M 107.29M 112.42M 92.51M 94.66M 95.69M 93.95M 94.8M 98.81M 92.52M 87.67M 81.98M 74.59M 72.33M
Interest Expense
n/a n/a n/a n/a 1.27M 2.02M 2.83M 3.64M 3.17M 3.13M 3.03M 2.94M 2.84M 2.84M 2.84M 2.85M 2.5M 1.99M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
66.92M 86.61M 82.81M 101.44M 103.09M 107.29M 112.42M 93.11M 95.81M 97.33M 96.24M 96.81M 100.89M 94.69M 89.67M 83.66M 75.65M 72.8M
Income Tax Expense
287K 287K 287K -19M -19M -19M -19M -288K -609K -609K -609K -183K 15.97M 15.97M 15.97M 15.83M n/a n/a
Shares Outstanding (Basic)
25.98M 25.9M 25.91M 21.47M 16.72M 5.41M 5.17M 5.16M 5.11M 5.11M 4.83M 5.09M 4.95M 4.14M 3.84M 3.84M 3.15M 3.08M
Shares Outstanding (Diluted)
26.45M 25.9M 25.91M 21.47M 17.79M 5.41M 5.17M 5.16M 5.11M 5.11M 4.83M 5.09M 4.95M 4.14M 3.84M 3.84M 3.37M 3.08M
EPS (Basic)
-3.63 -3.56 -13.38 -47.74 -46.09 -48.9 -42.64 -7.05 -6.81 -2.84 8.35 10.31 7.15 6.62 -6.99 -14.41 -12.52 -21.19
EPS (Diluted)
-3.64 -3.6 -13.42 -47.78 -46.13 -48.9 -42.64 -7.05 -6.86 -2.89 8.12 9.92 6.81 6.20 -7.23 -14.49 -12.6 -21.19
EBITDA
-75.92M -40.08M -75.99M -262.89M -246.53M -270.58M -234.17M -30.77M -30.1M -10.28M 40.09M 46.48M 52.62M 48.66M -4.87M -32.51M -40.78M -70.15M
EBIT
-56.04M -42.2M -77.14M -263.83M -247.38M -271.85M -235.88M -32.81M -32.49M -12.54M 37.8M 44.48M 50.53M 46.49M -6.88M -34.7M -42.71M -71.86M
Depreciation & Amortization
1.93M 2.12M 1.15M 937K 840K 1.27M 1.7M 2.04M 2.39M 2.26M 2.29M 2M 2.09M 2.17M 2.01M 1.93M 1.44M 982K